Blog

Results from the Phase 3 NADINA Clinical Trial – Melanoma Institute Australia

A collage photo of Georgina Long and Christian Blank

Jun 6, 2024, 02:56

Results from the Phase 3 NADINA Clinical Trial – Melanoma Institute Australia

Melanoma Institute Australia posted on LinkedIn:

“Heralded as a cancer treatment revolution, the pre-surgery (neoadjuvant) use of combination immunotherapy looks set to become standard treatment for melanoma, and to impact other cancers across the globe.

Ground-breaking results from the Phase 3 NADINA Clinical Trial, an international collaboration co-led by MIA’s Prof Georgina Long and Prof Christian Blank from The Netherlands Cancer Institute.”

Source: Melanoma Institute Australia/LinkedIn

cancer Christian Blank combination immunotherapy Georgina Long Melanoma Melanoma Institute Australia NADINA Clinical Trial OncoDaily Oncology The Netherlands Cancer Institute

Esophageal Cancer: Symptoms, Causes, Stages, Diagnosis & Treatment

Faster, Flexible and Affordable: Mikhail Groubman on Building a Global Legacy in Clinical Research in an Untapped Market

Invest in Health Policy: A Conversation with Professor Andreas Charalambous

FDA Approves Cosibelimab-ipdl for Treatment of Metastatic or Locally Advanced Cutaneous Squamous Cell Carcinoma

Dolph Lundgren’s Fight for Life: How He Survived Kidney Cancer After 9 Years of Battle

Special Coverage